ASBPW · Aspire Biopharma Holdings, Inc.

This 8-K/A reports the successful closing of the second tranche of Aspire Biopharma’s $21 million private placement of Series A Convertible Preferred Stock — a material financing event with direct strategic implications. The $10 million second tranche, closed April 15, 2026, completes the previously announced offering framework and delivers near-term capital to execute the company’s stated acquisition strategy, specifically funding the cash portion of the proposed Dura Driver Control Systems deal. Combined with the February 6, 2026 first tranche ($11 million), the full $21 million gross proceeds (pre-fee) significantly strengthens the balance sheet ahead of a transformative M&A step. Critically, the concurrent filing of the Certificate of Amendment on April 13, 2026 — increasing the authorized Series A shares to 30,000 — not only formalizes the expanded issuance capacity but also signals preparedness for potential additional closings under identical terms, enhancing financial flexibility. The involvement of RBW Capital Partners via Dawson James Securities Inc. as placement agent adds credibility to the capital raise process and suggests institutional-level due diligence was conducted. For investors, this filing confirms execution against the company’s capital strategy, de-risks near-term funding for the Dura Driver acquisition, and establishes a clear, documented path to deploying proceeds — all without diluting common shareholders yet, as conversion remains contingent on future triggers. The absence of earnings, governance changes, or regulatory disclosures further concentrates materiality on this financing and its direct operational enablers.